DOCSLIB.ORG

BD Biosciences New RUO Reagents - November 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BD Biosciences New RUO Reagents - November 2020 BD Biosciences New RUO reagents - November 2020 Reactivity Description Format Clone Size Cat. number Hu CD133 FITC W6B3C1 100µg 567029 Hu CD133 FITC W6B3C1 25µg 567033 Hu CD39 PE A1/CD39 100Tst 567156 Hu CD39 PE A1/CD39 25Tst 567157 Hu KIR2DL1/S1/S3/S5 PE HP-MA4 100Tst 567158 Hu KIR2DL1/S1/S3/S5 PE HP-MA4 25Tst 567159 Hu IL-22 Alexa Fluor® 647 MH22B2 100µg 567160 Hu IL-22 Alexa Fluor® 647 MH22B2 25µg 567161 Hu CD99 R718 TU12 50µg 751651 Hu CD161 R718 DX12 50µg 751652 Hu CD116 R718 HGMCSFR-M1 50µg 751653 Hu HLA-G R718 87G 50µg 751670 Hu CD27 R718 O323 50µg 751686 Hu CD80 (B7-1) R718 2D10.4 50µg 751737 Hu Integrin αvβ5 R718 ALULA 50µg 751738 Hu CD266 (Tweak-R) R718 ITEM-4 50µg 751739 Hu ErbB3 (HER-3) R718 SGP1 50µg 751799 Hu TCR Vβ5.1 R718 LC4 50µg 751816 Hu CD123 (IL-3Ra) R718 6H6 50µg 751844 Hu CD1a R718 SK9 50µg 751847 Hu CD20 R718 L27 50µg 751849 Hu Disial GD2 R718 14.G2A 50µg 751851 Reactivity Description Format Clone Size Cat. number Hu CD71 R718 L01.1 50µg 751853 Hu CD278 (ICOS) R718 DX29 50µg 751854 Hu B7-H4 R718 MIH43 50µg 751857 Hu CD53 R718 HI29 50µg 751858 Hu CD197 (CCR7) R718 2-L1-A 50µg 751859 Hu CD197 (CCR7) R718 3D12 50µg 751861 Hu CD31 R718 L133.1 50µg 751863 Hu EGF Receptor R718 EMAB-134 50µg 751864 Hu CD8b R718 2ST8.5H7 50µg 751867 Hu CD31 R718 MBC 78.2 50µg 751869 Hu CD162 R718 KPL-1 50µg 751873 Hu CD24 R718 ML5 50µg 751874 Hu CD159C (NKG2C) R718 134591 50µg 751876 Hu CD169 (Siglec-1) R718 7-239 50µg 751877 Hu CD16b R718 CLB-GRAN11.5 50µg 751880 Hu IgM R718 UCH-B1 50µg 751881 Hu CD275 R718 2D3/B7-H2 50µg 751883 Hu CD307e (FCRL5) R718 509F6 50µg 751885 Hu CD66 R718 B1.1/CD66 50µg 751886 Hu CD164 R718 N6B6 50µg 751887 Hu C3a Receptor R718 HC3ARZ8 50µg 751888 Hu HLA-C R718 DT-9 50µg 751891 Hu Delta-Like Protein 4 R718 MHD4-46 50µg 751893 Hu TCR Vβ8 R718 JR2 50µg 751894 Hu CMRF-56 R718 CMRF-56 50µg 751896 Hu LDLR R718 C7 50µg 751897 Hu CD204 (MSR1) R718 U23-56 50µg 751904 Hu TCR Vα7.2 R718 OF-5A12 50µg 751905 Hu CD97 R718 VIM3B 50µg 751906 Hu ROR1 R718 4A5 50µg 751907 Hu CD154 R718 TRAP1 50µg 751914 Hu CD119 R718 GIR-208 50µg 751915 Hu CD114 R718 LMM741 50µg 751916 Hu IgG R718 G18-145 50µg 751917 Hu EphA2 R718 371805 50µg 751918 Hu CD86 R718 BU63 50µg 751920 Hu CD274 (B7-H1) R718 MIH1 50µg 751922 Hu CD140b R718 28D4 50µg 751924 Hu CD9 R718 M-L13 50µg 751928 Hu CD276 R718 7-517 50µg 751929 Hu CD235a R718 GA-R2 (HIR2) 50µg 751931 Hu CD326 (EPCAM) R718 KS1/4 50µg 751932 Hu HLA-DR, DP, DQ R718 TU39 50µg 751934 Hu CD33 R718 P67.6 50µg 751936 Hu CD44 R718 G44-26 50µg 751938 Hu CD104 R718 439-9B 50µg 751940 Hu CD81 (TAPA-1) R718 JS-81 50µg 751941 Reactivity Description Format Clone Size Cat. number Hu CD326 R718 EBA-1 50µg 751942 Hu CD193 R718 5E8 50µg 751944 Hu CD243 R718 UIC2 50µg 751945 Hu CD294 (CRTH2) R718 BM16 50µg 751948 Hu CD201 R718 RCR-252 50µg 751949 Hu CD303 (BDCA-2) R718 V24-785 50µg 751950 Hu HLA-A3 R718 GAP.A3 50µg 751952 Hu CD8 R718 G42-8 50µg 751953 Hu BLTR-1 R718 203/14F11 50µg 751954 Hu TCR Vβ3 R718 JOVI.3 50µg 751957 Hu CD226 R718 DX11 50µg 751963 Hu CD50 R718 TU41 50µg 751965 Hu CD87 R718 VIM5 50µg 751966 Hu CD34 R718 563 50µg 751969 Hu CD268 (BAFF Receptor) R718 11C1 50µg 751971 Hu CD182 R718 6C6 50µg 751972 Hu CD192 (CCR2) R718 LS132.1D9 50µg 751973 Hu CD186 (CXCR6) R718 13B1E5 50µg 751975 Hu CD222 R718 MEM-238 50µg 751976 Hu CD3 R718 SK7 50µg 751978 Hu Podoplanin R718 LPMAB-23 50µg 751982 Hu CD62P R718 AK-4 50µg 751983 Hu CD56 R718 NCAM16.2 50µg 751984 Hu CD79b R718 3A2-2E7 50µg 751985 Hu CD180 R718 G28-8 50µg 751989 Hu Neuropilin-1 R718 U21-1283 50µg 751990 Hu CD39 R718 TU66 50µg 751992 Hu CD28 R718 L293 50µg 751994 Hu CD365 (TIM-1) R718 1D12 50µg 751996 Hu CD206 R718 19.2 50µg 751998 Hu CD307c R718 H5 50µg 751999 Hu CD115 (CSF-1R) R718 9-4D2-1E4 50µg 752001 Hu CD172g (SIRPγ) R718 OX-119 50µg 752002 Hu Delta-Like Protein 1 R718 MHD1-314 50µg 752005 Hu CD103 R718 BER-ACT8 50µg 752007 Hu CD300c R718 TX45 50µg 752008 Hu CD44 R718 L178 50µg 752010 Hu CD32 R718 3D3 50µg 752011 Hu CXCR5 R718 RF8B2 50µg 752012 Hu Kappa R718 G20-193 50µg 752017 Hu CD337 (NKp30) R718 P30-15 50µg 752018 Hu CD300f (IREM-1) R718 UP-D1 50µg 752022 Hu γδ TCR R718 11F2 50µg 752023 Hu Ig, κ light chain R718 TB28-2 50µg 752024 Hu CD44 R718 515 50µg 752028 Hu CD35 R718 E11 50µg 752029 Hu CD123 R718 9F5 50µg 752032 Reactivity Description Format Clone Size Cat. number Hu CD134 R718 L106 50µg 752035 Hu CD144 R718 55-7H1 50µg 752036 Hu CD157 R718 SY/11B5 50µg 752038 Hu CD101 R718 V7.1 50µg 752039 Hu CLIP R718 CERCLIP 50µg 752041 Hu CD105 R718 266 50µg 752042 Hu CD324 R718 67A4 50µg 752043 Hu SSEA-5 R718 8E11/SSEA-5 50µg 752044 Hu CD13 R718 WM15 50µg 752048 Hu CD171 R718 5G3 50µg 752049 Hu CD61 R718 RUU-PL7F12 50µg 752050 Hu CD47 R718 B6H12 50µg 752051 Hu EGF Receptor R718 EGFR.1 50µg 752054 Hu CD26 R718 L272 50µg 752055 Hu CD307d (FCRL4) R718 A1/CD307D 50µg 752056 Hu HLA-DQ R718 TU169 50µg 752058 Hu CD106 R718 51-10C9 50µg 752061 Hu CD2 R718 RPA-2.10 50µg 752063 Hu IgE R718 G7-26 50µg 752064 Hu CD93 R718 R139 50µg 752065 Hu CD42a R718 ALMA.16 50µg 752068 Hu CD163 R718 GHI/61 50µg 752069 Hu CD147 R718 HIM6 50µg 752070 Hu CD172b R718 B4B6 50µg 752071 Hu CD62L R718 SK11 50µg 752074 Hu CD73 R718 AD2 50µg 752076 Hu CD7 R718 M-T701 50µg 752079 Hu TSPAN8 R718 458811 50µg 752080 Hu CD11b R718 D12 50µg 752081 Hu CD158b1/b2/j R718 DX27 50µg 752082 Hu CD49b R718 AK-7 50µg 752084 Hu CD4v4 R718 L120 50µg 752085 Hu CD62P R718 AC1.2 50µg 752086 Hu CD43 R718 L60 50µg 752087 Hu EphB2 R718 2H9 50µg 752089 Hu CD195 R718 2D7/CCR5 50µg 752091 Hu CD56 R718 MY31 50µg 752092 Hu CD46 R718 E4.3 50µg 752095 Hu CD29 R718 MAR4 50µg 752098 Hu CD140a R718 ALPHA R1 50µg 752099 Hu CD14 R718 MPHIP9 50µg 752101 Hu CD72 R718 J4-117 50µg 752102 Hu CD129 (IL-9R) R718 AH9R7 50µg 752104 Hu CD238 R718 BRIC 203 50µg 752108 Hu CD55 R718 IA10 50µg 752109 Hu CD270 (HVEM) R718 CW10 50µg 752111 Hu CD2 R718 L303.1 50µg 752112 Reactivity Description Format Clone Size Cat. number Hu CD36 R718 CLB-IVC7 50µg 752116 Hu CD21 R718 B-LY4 50µg 752117 Hu CD89 R718 A59 50µg 752119 Hu CD307a (FCRL1) R718 E3 50µg 752120 Hu SUSD2 R718 W5C5 50µg 752122 Hu CD66c R718 B6.2/CD66 50µg 752123 Hu CD42b R718 HIP1 50µg 752125 Hu CD165 R718 SN2 50µg 752127 Hu CD325 (N-Cadherin) R718 8C11 50µg 752128 Hu Trop-2 R718 162-46 50µg 752129 Hu CD137 Ligand R718 C65-485 50µg 752131 Hu CD49a R718 SR84 50µg 752133 Hu CD13 R718 L138 50µg 752134 Hu CD58 R718 1C3 50µg 752136 Hu ASGPR 1 R718 8D7 50µg 752137 Hu CD100 (Sema4D) R718 A8 50µg 752138 Hu CD62E R718 68-5H11 50µg 752142 Hu CD243 (P-gp) R718 15D3 50µg 752143 Hu Claudin-1 R718 421203 50µg 752144 Hu CD25 R718 2A3 50µg 752147 Hu CD2 R718 S5.2 50µg 752148 Hu AKP R718 B4-78 50µg 752149 Hu CD91 R718 A2MR-A2 50µg 752150 Hu CD177 R718 MEM-166 50µg 752151 Hu CD134 R718 ACT35 50µg 752153 Hu CD273 R718 MIH18 50µg 752154 Hu CD49d R718 L25 50µg 752156 Hu CD146 R718 P1H12 50µg 752158 Hu CD71 R718 M-A712 50µg 752159 Hu CD27 R718 L128 50µg 752160 Hu CD4 R718 M-T477 50µg 752165 Hu CD92 R718 VIM15 50µg 752166 Hu CD131 R718 3D7 50µg 752168 Hu CD1c R718 F10/21A3 50µg 752169 Hu CD21 R718 1048 50µg 752172 Hu CD10 R718 MEM-78 50µg 752173 Hu CD45RB R718 MT4 (6B6) 50µg 752175 Hu CD34 R718 8G12 50µg 752176 Hu CD282 R718 11G7 50µg 752177 Hu CD340 (HER-2) R718 24D2 50µg 752178 Hu CD11a R718 G43-25B 50µg 752181 Hu CD26 R718 M-A261 50µg 752183 Hu CD31 R718 M89D3 50µg 752186 Hu Notch1 R718 MHN1-519 50µg 752187 Hu CD156c R718 11G2 50µg 752189 Hu FcεR1α R718 AER-37 50µg 752192 Hu CD344 R718 CH3A4A7 50µg 752194 Reactivity Description Format Clone Size Cat. number Hu CD85g (ILT7) R718 17G10.2 50µg 752195 Hu HLA-ABC R718 G46-2.6 50µg 752196 Hu CX3CR1 R718 2A9-1 50µg 752200 Hu CD109 R718 TEA 2/16 50µg 752201 Hu CD196 (CCR6) R718 11A9 50µg 752203 Hu CD271 R718 C40-1457 50µg 752204 Hu CD277 R718 232-5 50µg 752207 Hu CD98 R718 UM7F8 50µg 752208 Hu Platelet GPVI R718 HY101 50µg 752209 Hu CD94 R718 HP-3D9 50µg 752211 Hu BAH-1 R718 BAH-1 50µg 752213 Hu TSLP Receptor R718 1F11/TSLPR 50µg 752214 Hu Lgr5 R718 4D11F8 50µg 752215 Hu CD49c R718 C3 II.1 50µg 752217 Hu Axl R718 108724 50µg 752219 Hu CD18 R718 6.7 50µg 752220 Hu Siglec-8 R718 837535 50µg 752222 Hu Light Chain, λ R718 JDC-12 50µg 752228 Hu CD272 (BTLA) R718 J168-540 50µg 752231 Hu CD243 (P-gp) R718 17F9 50µg 752232 Hu CD51/CD61 R718 23C6 50µg 752235 Hu PI-16 R718 CRCBT-02-001 50µg 752237 Hu CD102 R718 CBR-IC2/2 50µg 752240 Hu CD266 R718 ITEM-1 50µg 752241 Hu Invariant NK T Cell R718 6B11 50µg 752243 Hu CD334 R718 4FR6D3 50µg 752244 Hu CD227 (MUC1) R718 HMPV 50µg 752245 Hu CD11a R718 G-25.2 50µg 752246 Hu Ig, λ Light Chain R718 1-155-2 50µg 752247 Hu CD142 R718 HTF-1 50µg 752248 Hu Lgr5 R718 8F2 50µg 752250 Hu MICA R718 159227 50µg 752253 Hu CD181 R718 5A12 50µg 752255 Hu CD45RA R718 5H9 50µg 752257 Hu Vγ9 TCR R718 B3 50µg 752259 Hu CD249 R718 2D3/APA 50µg 752260 Hu CD22 R718 HIB22 50µg 752263 Hu CD18 R718 L130 50µg 752264 Hu CLEC-2A (PILAR) R718 705518 50µg 752265 Hu CD305 (LAIR-1) R718 DX26 50µg 752267 Hu CD195 R718 3A9 50µg 752268 Hu CD23 R718 EBVCS-5 50µg 752269 Hu CD32 R718 FLI8.26 50µg 752270 Hu CD43 R718 1G10 50µg 752273 Hu CD108 R718 KS-2 50µg 752274 Hu CD49d R718 9F10 50µg 752276 Hu CD151 R718 14A2.H1 50µg 752277 Reactivity Description Format Clone Size Cat.
Load more

Recommended publications
  • The 'C3ar Antagonist' SB290157 Is a Partial C5ar2 Agonist
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.01.232090; this version posted August 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. The ‘C3aR antagonist’ SB290157 is a partial C5aR2 agonist Xaria X. Li1, Vinod Kumar1, John D. Lee1, Trent M. Woodruff1* 1School of Biomedical Sciences, The University of Queensland, St Lucia, 4072 Australia. * Correspondence: Prof. Trent M. Woodruff School of Biomedical Sciences, The University of Queensland, St Lucia, 4072 Australia. Ph: +61 7 3365 2924; Fax: +61 7 3365 1766; E-mail: [email protected] Keywords: Complement C3a, C3aR, SB290157, C5aR1, C5aR2 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.01.232090; this version posted August 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abbreviations used in this article: BRET, bioluminescence resonance energy transfer; BSA, bovine serum albumin; C3aR, C3a receptor C5aR1, C5a receptor 1; CHO-C3aR, Chinese hamster ovary cells stably expressing C3aR; CHO-C5aR1, Chinese hamster ovary cells stably expressing C5aR1; DMEM, Dulbecco's Modified Eagle's Medium; ERK1/2, extracellular signal-regulated kinase 1/2; FBS, foetal bovine serum; HEK293, human embryonic kidney 293 cells; HMDM, human monocyte-derived macrophage; i.p., intraperitoneal; i.v., intravenous; rhC5a, recombinant human C5a; RT, room temperature; S.E.M.
    [Show full text]
  • Profound Treg Perturbations Correlate with COVID-19 Severity
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.11.416180; this version posted December 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Profound Treg perturbations correlate with COVID-19 severity Silvia Galván-Peña1*, Juliette Leon1,2*, Kaitavjeet Chowdhary1, Daniel A. Michelson1, Brinda Vijaykumar1, Liang Yang1, Angela Magnuson1, Zachary Manickas-Hill3,4, Alicja Piechocka- Trocha3,4, Daniel P. Worrall3,4, Kathryn E. Hall3,5, Musie Ghebremichael3,4, Bruce D. Walker3,4,6, Jonathan Z. Li3,7, Xu G. Yu3,4, MGH COVID-19 Collection & Processing Team, Diane Mathis1 and Christophe Benoist1,8,+ 1Department of Immunology, Harvard Medical School, Boston, MA, USA 2 INSERM UMR 1163, University of Paris, Imagine Institute, Paris, France 3Massachusetts Consortium on Pathogen Readiness, Boston, MA, USA 4Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA 5Department of Medicine, Massachusetts General Hospital, Boston, MA, USA 6Howard Hughes Medical Institute, Center for the AIDS Programme of Research in South Africa. 7Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA 8Lead contact * Equal contribution +Address correspondence to: Christophe Benoist Department of Immunology Harvard Medical School 77 Avenue Louis Pasteur, Boston, MA 02115 e-mail: [email protected] Phone: (617) 432-7741 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.11.416180; this version posted December 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
    [Show full text]
  • Gene List HTG Edgeseq Immuno-Oncology Assay
    Gene List HTG EdgeSeq Immuno-Oncology Assay Adhesion ADGRE5 CLEC4A CLEC7A IBSP ICAM4 ITGA5 ITGB1 L1CAM MBL2 SELE ALCAM CLEC4C DST ICAM1 ITGA1 ITGA6 ITGB2 LGALS1 MUC1 SVIL CDH1 CLEC5A EPCAM ICAM2 ITGA2 ITGAL ITGB3 LGALS3 NCAM1 THBS1 CDH5 CLEC6A FN1 ICAM3 ITGA4 ITGAM ITGB4 LGALS9 PVR THY1 Apoptosis APAF1 BCL2 BID CARD11 CASP10 CASP8 FADD NOD1 SSX1 TP53 TRAF3 BCL10 BCL2L1 BIRC5 CASP1 CASP3 DDX58 NLRP3 NOD2 TIMP1 TRAF2 TRAF6 B-Cell Function BLNK BTLA CD22 CD79A FAS FCER2 IKBKG PAX5 SLAMF1 SLAMF7 SPN BTK CD19 CD24 EBF4 FASLG IKBKB MS4A1 RAG1 SLAMF6 SPI1 Cell Cycle ABL1 ATF1 ATM BATF CCND1 CDK1 CDKN1B NCL RELA SSX1 TBX21 TP53 ABL2 ATF2 AXL BAX CCND3 CDKN1A EGR1 REL RELB TBK1 TIMP1 TTK Cell Signaling ADORA2A DUSP4 HES1 IGF2R LYN MAPK1 MUC1 NOTCH1 RIPK2 SMAD3 STAT5B AKT3 DUSP6 HES5 IKZF1 MAF MAPK11 MYC PIK3CD RNF4 SOCS1 STAT6 BCL6 ELK1 HEY1 IKZF2 MAP2K1 MAPK14 NFATC1 PIK3CG RORC SOCS3 SYK CEBPB EP300 HEY2 IKZF3 MAP2K2 MAPK3 NFATC3 POU2F2 RUNX1 SPINK5 TAL1 CIITA ETS1 HEYL JAK1 MAP2K4 MAPK8 NFATC4 PRKCD RUNX3 STAT1 TCF7 CREB1 FLT3 HMGB1 JAK2 MAP2K7 MAPKAPK2 NFKB1 PRKCE S100B STAT2 TYK2 CREB5 FOS HRAS JAK3 MAP3K1 MEF2C NFKB2 PTEN SEMA4D STAT3 CREBBP GATA3 IGF1R KIT MAP3K5 MTDH NFKBIA PYCARD SMAD2 STAT4 Chemokine CCL1 CCL16 CCL20 CCL25 CCL4 CCR2 CCR7 CX3CL1 CXCL12 CXCL3 CXCR1 CXCR6 CCL11 CCL17 CCL21 CCL26 CCL5 CCR3 CCR9 CX3CR1 CXCL13 CXCL5 CXCR2 MST1R CCL13 CCL18 CCL22 CCL27 CCL7 CCR4 CCRL2 CXCL1 CXCL14 CXCL6 CXCR3 PPBP CCL14 CCL19 CCL23 CCL28 CCL8 CCR5 CKLF CXCL10 CXCL16 CXCL8 CXCR4 XCL2 CCL15 CCL2 CCL24 CCL3 CCR1 CCR6 CMKLR1 CXCL11 CXCL2 CXCL9 CXCR5
    [Show full text]
  • The Expression and Regulation of Chemerin in the Epidermis
    RESEARCH ARTICLE The Expression and Regulation of Chemerin in the Epidermis Magdalena Banas1, Aneta Zegar1, Mateusz Kwitniewski1, Katarzyna Zabieglo1, Joanna Marczynska1, Monika Kapinska-Mrowiecka2, Melissa LaJevic3,4, Brian A. Zabel4, Joanna Cichy1* 1 Department of Immunology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland, 2 Department of Dermatology, Zeromski Hospital, Kraków, Poland, 3 Stanford University School of Medicine, Department of Pathology, Stanford, California, United States of America, 4 Palo Alto Veterans Institute for Research, VA Palo Alto Health Care System, Palo Alto, California, United States of America * [email protected] Abstract OPEN ACCESS Chemerin is a protein ligand for the G protein-coupled receptor CMKLR1 and also binds to two atypical heptahelical receptors, CCRL2 and GPR1. Chemerin is a leukocyte attractant, Citation: Banas M, Zegar A, Kwitniewski M, Zabieglo K, Marczynska J, Kapinska-Mrowiecka M, et al. adipokine, and antimicrobial protein. Although chemerin was initially identified as a highly (2015) The Expression and Regulation of Chemerin expressed gene in healthy skin keratinocytes that was downregulated during psoriasis, the in the Epidermis. PLoS ONE 10(2): e0117830. regulation of chemerin and its receptors in the skin by specific cytokines and microbial fac- doi:10.1371/journal.pone.0117830 tors remains unexplored. Here we show that chemerin, CMKLR1, CCRL2 and GPR1 are Academic Editor: Bernhard Ryffel, French National expressed in human and mouse epidermis, suggesting that this tissue may be both a Centre for Scientific Research, FRANCE source and target for chemerin mediated effects. In human skin cultures, chemerin is signifi- Received: October 1, 2014 cantly downregulated by IL-17 and IL-22, key cytokines implicated in psoriasis, whereas it is Accepted: December 31, 2014 upregulated by acute phase cytokines oncostatin M and IL-1β.
    [Show full text]
  • Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association Between BMI and Adult-Onset Non- Atopic
    Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association between BMI and Adult-Onset Non- Atopic Asthma Ayoung Jeong 1,2, Medea Imboden 1,2, Akram Ghantous 3, Alexei Novoloaca 3, Anne-Elie Carsin 4,5,6, Manolis Kogevinas 4,5,6, Christian Schindler 1,2, Gianfranco Lovison 7, Zdenko Herceg 3, Cyrille Cuenin 3, Roel Vermeulen 8, Deborah Jarvis 9, André F. S. Amaral 9, Florian Kronenberg 10, Paolo Vineis 11,12 and Nicole Probst-Hensch 1,2,* 1 Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland; [email protected] (A.J.); [email protected] (M.I.); [email protected] (C.S.) 2 Department of Public Health, University of Basel, 4001 Basel, Switzerland 3 International Agency for Research on Cancer, 69372 Lyon, France; [email protected] (A.G.); [email protected] (A.N.); [email protected] (Z.H.); [email protected] (C.C.) 4 ISGlobal, Barcelona Institute for Global Health, 08003 Barcelona, Spain; [email protected] (A.-E.C.); [email protected] (M.K.) 5 Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain 6 CIBER Epidemiología y Salud Pública (CIBERESP), 08005 Barcelona, Spain 7 Department of Economics, Business and Statistics, University of Palermo, 90128 Palermo, Italy; [email protected] 8 Environmental Epidemiology Division, Utrecht University, Institute for Risk Assessment Sciences, 3584CM Utrecht, Netherlands; [email protected] 9 Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College, SW3 6LR London, UK; [email protected] (D.J.); [email protected] (A.F.S.A.) 10 Division of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; [email protected] 11 MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, W2 1PG London, UK; [email protected] 12 Italian Institute for Genomic Medicine (IIGM), 10126 Turin, Italy * Correspondence: [email protected]; Tel.: +41-61-284-8378 Int.
    [Show full text]
  • An Overview on G Protein-Coupled Receptor-Induced Signal Transduction in Acute Myeloid Leukemia
    An overview on G protein-coupled receptor-induced signal transduction in Acute Myeloid Leukemia 1* 1,3 4,5,6 2* Frode Selheim , Elise Aasebø , Catalina Ribas and Anna M. Aragay 1The Proteomics Unit at the University of Bergen, Department of Biomedicine, University of Bergen, Jonas Lies vei 91, 5020 Bergen, Norway; 3 Department of Clinical Science, University of Bergen, Jonas Lies vei 87, 5021 Bergen, Norway; [email protected]. 2Departamento de Biologia Celular. Instituto de Biología Molecular de Barcelona (IBMB-CSIC), Spanish National Research Council (CSIC), Baldiri i Reixac, 15, 08028 Barcelona, Spain; [email protected]. 4Departamento de Biología Molecular and Centro de Biología Molecular “Severo Ochoa” (UAM-CSIC), 28049 Madrid, Spain; 5Instituto de Investigación Sanitaria La Princesa, 28006 Madrid, Spain; 6CIBER de Enfermedades Cardiovasculares, ISCIII (CIBERCV), 28029 Madrid, Spain, [email protected] * Corresponding authors: Frode Selheim Adr: Jonas Lies vei 91, 5020 Bergen, Norway Email: [email protected], Tel:+4755586091 Anna M. Aragay Adr: Baldiri i Reixac, 15, 08028 Barcelona. Spain. E-mail: [email protected]; Tel.: +934098671 1 Abstract Background: Acute myeloid leukemia (AML) is a genetically heterogeneous disease characterized by uncontrolled proliferation of precursor myeloid-lineage cells in the bone marrow. AML is also characterized with patients with poor long-term survival outcomes due to relapse. Many efforts have been made to understand the biological heterogeneity of AML and the challenges to develop new therapies are therefore enormous. G protein-coupled receptors (GPCRs) are a large attractive drug targeted family of transmembrane proteins, and aberrant GPCR expression and GPCR-mediated signaling have been implicated in leukemogenesis of AML.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • Malaria Polyclonal B Cell Activator Activation of the Memory
    Increased B Cell Survival and Preferential Activation of the Memory Compartment by a Malaria Polyclonal B Cell Activator This information is current as Daria Donati, Bobo Mok, Arnaud Chêne, Hong Xu, Mathula of October 2, 2021. Thangarajh, Rickard Glas, Qijun Chen, Mats Wahlgren and Maria Teresa Bejarano J Immunol 2006; 177:3035-3044; ; doi: 10.4049/jimmunol.177.5.3035 http://www.jimmunol.org/content/177/5/3035 Downloaded from References This article cites 35 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/177/5/3035.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 2, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Increased B Cell Survival and Preferential Activation of the Memory Compartment by a Malaria Polyclonal B Cell Activator1 Daria Donati,2† Bobo Mok,* Arnaud Cheˆne,*† Hong Xu,† Mathula Thangarajh,‡ Rickard Glas,† Qijun Chen,§ Mats Wahlgren,* and Maria Teresa Bejarano*† Chronic malaria infection is characterized by polyclonal B cell activation, hyperglobulinemia, and elevated titers of autoantibod- ies.
    [Show full text]
  • Program in Lupus Monocytes to Turn on a Migratory Dendritic Cell IFN
    IFN Priming Is Necessary but Not Sufficient To Turn on a Migratory Dendritic Cell Program in Lupus Monocytes This information is current as Alicia Rodriguez-Pla, Pinakeen Patel, Holden T. Maecker, of September 28, 2021. Jose Rossello-Urgell, Nicole Baldwin, Lynda Bennett, Victoria Cantrell, Jeanine Baisch, Marilynn Punaro, Alisa Gotte, Lorien Nassi, Tracey Wright, Anna Karolina Palucka, Jacques Banchereau and Virginia Pascual J Immunol 2014; 192:5586-5598; Prepublished online 14 Downloaded from May 2014; doi: 10.4049/jimmunol.1301319 http://www.jimmunol.org/content/192/12/5586 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2014/05/14/jimmunol.130131 Material 9.DCSupplemental References This article cites 70 articles, 26 of which you can access for free at: http://www.jimmunol.org/content/192/12/5586.full#ref-list-1 Why The JI? Submit online. by guest on September 28, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2014 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606.
    [Show full text]
  • Novel Therapies for Eosinophilic Disorders
    Novel Therapies for Eosinophilic Disorders Bruce S. Bochner, MD KEYWORDS Eosinophil Therapies Antibodies Targets Pharmacology Biomarkers KEY POINTS A sizable unmet need exists for new, safe, selective, and effective treatments for eosinophil-associated diseases, such as hypereosinophilic syndrome, eosinophilic gastrointestinal disorders, nasal polyposis, and severe asthma. An improved panel of biomarkers to help guide diagnosis, treatment, and assessment of disease activity is also needed. An impressive array of novel therapeutic agents, including small molecules and biologics, that directly or indirectly target eosinophils and eosinophilic inflammation are undergoing controlled clinical trials, with many already showing promising results. A large list of additional eosinophil-related potential therapeutic targets remains to be pursued, including cell surface structures, soluble proteins that influence eosinophil biology, and eosinophil-derived mediators that have the potential to contribute adversely to disease pathophysiology. INTRODUCTION Eosinophilic disorders, also referred to as eosinophil-associated diseases, consist of a range of infrequent conditions affecting virtually any body compartment and organ.1 The most commonly affected areas include the bone marrow, blood, mucosal sur- faces, and skin, often with immense disease- and treatment-related morbidity, Disclosure Statement: Dr Bochner’s research efforts are supported by grants AI072265, AI097073 and HL107151 from the National Institutes of Health. He has current or recent consul- ting or scientific advisory board arrangements with, or has received honoraria from, Sanofi-A- ventis, Pfizer, Svelte Medical Systems, Biogen Idec, TEVA, and Allakos, Inc. and owns stock in Allakos, Inc. and Glycomimetics, Inc. He receives publication-related royalty payments from Elsevier and UpToDate and is a coinventor on existing and pending Siglec-8-related patents and, thus, may be entitled to a share of future royalties received by Johns Hopkins University on the potential sales of such products.
    [Show full text]
  • International Union of Basic and Clinical Pharmacology. LXXXVII
    Supplemental Material can be found at: /content/suppl/2014/09/18/65.1.500.DC1.html 1521-0081/65/1/500–543$25.00 http://dx.doi.org/10.1124/pr.111.005223 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:500–543, January 2013 Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics International Union of Basic and Clinical Pharmacology. LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors Andreas Klos, Elisabeth Wende, Kathryn J. Wareham, and Peter N. Monk Department for Medical Microbiology, Medical School Hannover, Hannover, Germany (A.K., E.W.); and the Department of Infection and Immunity, University of Sheffield Medical School, Sheffield, United Kingdom (K.J.W., P.N.M.) Abstract. ....................................................................................502 I. Introduction. ..............................................................................503 A. Production of Complement Peptides......................................................503 B. Concentrations of Complement Peptides in Health and Disease. .........................503 C. C3a and C5a Generation outside the Complement Cascade ...............................504 D. Deactivation of Complement Peptides ....................................................505 II. The Role of Complement Peptides in Pathophysiology . .....................................505 A. Complement Peptides Are Important Biomarkers of Disease..............................505 B. Functions of the Complement Peptides beyond Innate Immunity .........................506
    [Show full text]
  • Techniques for Immune Function Analysis Application Handbook 1St Edition
    Techniques for Immune Function Analysis Application Handbook 1st Edition BD Biosciences For additional information please access the Immune Function Homepage at www.bdbiosciences.com/immune_function For Research Use Only. Not for use in diagnostic or therapeutic procedures. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton Dickinson and Company is strictly prohibited. All applications are either tested in-house or reported in the literature. See Technical Data Sheets for details. BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. ©2003 BD Table of Contents Preface . 4 Chapter 1: Immunofluorescent Staining of Cell Surface Molecules for Flow Cytometric Analysis . 9 Chapter 2: BD™ Cytometric Bead Array (CBA) Multiplexing Assays . 35 Chapter 3: BD™ DimerX MHC:Ig Proteins for the Analysis of Antigen-specific T Cells. 51 Chapter 4: Immunofluorescent Staining of Intracellular Molecules for Flow Cytometric Analysis . 61 Chapter 5: BD FastImmune™ Cytokine Flow Cytometry. 85 Chapter 6: BD™ ELISPOT Assays for Cells That Secrete Biological Response Modifiers . 109 Chapter 7: ELISA for Specifically Measuring the Levels of Cytokines, Chemokines, Inflammatory Mediators and their Receptors . 125 Chapter 8: BD OptEIA™ ELISA Sets and Kits for Quantitation of Analytes in Serum, Plasma, and Cell Culture Supernatants. 143 Chapter 9: BrdU Staining and Multiparameter Flow Cytometric Analysis of the Cell Cycle . 155 Chapter 10: Cell-based Assays for Biological Response Modifiers . 177 Chapter 11: BD RiboQuant™ Multi-Probe RNase Protection Assay System .
    [Show full text]